Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 65% of retail investor accounts lose money when trading spread bets and CFDs with this provider. You should consider whether you understand how spread bets and CFDs work and whether you can afford to take the high risk of losing your money.
Open platformOpen platform

Daewoong Pharma Ends Southeast Asia Supply Deal With Abbott Worth KRW 69.23 Billion

By Public Technologies
  • Daewoong’s pharmaceutical subsidiary terminated its Southeast Asian pitavastatin calcium tablet supply contract with Abbott Products Operations, effective Feb. 28, 2024.
  • The canceled value totaled KRW 69.23 billion, equivalent to 8.24% of the subsidiary’s 2015 consolidated revenue.
  • The contract began Nov. 2, 2016, with an original value of KRW 72.8 billion; expiration was scheduled for Nov. 2, 2026.
  • Sales and payments received totaled KRW 3.57 billion, representing 4.91% of the original contract value.
  • Both parties agreed to terminate amid weak local sales, business difficulties and the subsidiary’s inability to maintain Korean product authorization.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Daewoong Co. Ltd. published the original content used to generate this news brief via DART, the regulatory disclosure system operated by the South Korea Financial Supervisory Service (FSS) (Ref. ID: 20261102800893), on November 02, 2026, and is solely responsible for the information contained therein.

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.
The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.
To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.
 

Cryptocurrency-related content is intended solely as news and market commentary. Crypto Derivatives are not available to Retail clients registered with Capital Com (UK) Ltd.